RBC Capital Reiterates Outperform on Evommune, Maintains $48 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintains $48 price target.
RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintains $48 price target.